Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396463 | 0.86 | NPC1 (0.58) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL3396461 | 0.86 | NPC1 (0.58) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL3185506 | 0.85 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3MAOB | |
| SCHEMBL3185502 | 0.85 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3MAOB | |
| SCHEMBL3195074 | 0.82 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL1949189 | 0.82 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| Hydrochloric Acid SCHEMBL1950394 | 0.81 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL3397861 | 0.80 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL3397863 | 0.80 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3MAOBRAB9A | |
| SCHEMBL3184057 | 0.79 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3MAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263617-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-09-11 | — | — | US | claimed |
| EP-2121677-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | claimed |
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEURO SEARCH A/S (DK) | 2010-02-04 | — | — | US | claimed |
| EP-2121677-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-11-25 | — | — | EP | claimed |
| WO-2008074797-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | WO | claimed |
| US-8263617-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-2121677-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEURO SEARCH A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| EP-2121677-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074797-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029711-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC6A2 | SLC6A4 8/4885SLC6A2 3/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.